3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

    PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

  • A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D MlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPUPG4{dU1? NIr0UGczcA>? M4DDOWROW09? MkT6doVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>? NGHFRoMzPTdzNkW2NS=>
A549  M2[xZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVmzcW0> MkPFNog> NIHibXlFVVOR MWLy[YR2[2W|IHfyc5d1cCCrbnjpZol1d3K7IHXm[oVkfCCxZjDCSG1E MlrRNlU4OTZ3NkG=
95D MoXXRZBweHSxc3nzJGF{e2G7 MUe1cW0> NHLXc3kzcA>? NWDOVFZMTE2VTx?= MYXpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? M1PncFI2PzF4NU[x
A549  MX\BdI9xfG:|aYOgRZN{[Xl? MmS0OY1O NFT5R5MzcA>? NWf4NXZZTE2VTx?= NYTv[mFWcW6qaXLpeJMhSkSPQz3pcoR2[2WmIHHwc5B1d3SrYzDj[YxtKGSnYYTo NHXiTXgzPTdzNkW2NS=>
NBL-W-S  NFTSVIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOxcW0> MV:2bC=> NIX1bGRmdmijbnPld{BISU6WLU[xJJRwgGmlaYT5 MXSyOVMzOzJ{Mh?=
NBL-W-S  M1PRNWFxd3C2b4Ppd{BCe3OjeR?= M4HGdVFuVQ>? MmXKOog> NECwSm5qdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBISU6WLU[x NF3GfFczPTN{M{KyNi=>
A2780cp  NFjOb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrmR2YydU1? NY[xWZBrOWh? NYTWWItWcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? MYeyOVMzOjZ7NB?=
A549  M1ziS2Z2dmO2aX;uJGF{e2G7 MUC1cW0> M4r1U|Jp MXXzeZBxemW|c3XzJHNRSyCrbnT1Z4VlKGGlY4XteYxifGmxbjDv[kBNSzNvSVm= MkH6NlUzQDV4Mki=
H157 MmTvSpVv[3Srb36gRZN{[Xl? NHe3eIQ2dU1? M2jP[FJp NYfKW2dle3WycILld5NmeyCVUFOgbY5lfWOnZDDhZ4N2dXWuYYTpc44hd2ZiTFOzMWlK MmrFNlUzQDV4Mki=
MDR NYPNWFJKSXCxcITvd4l{KEG|c3H5 NYTsbW1TOTCvTR?= MX:2bC=> M2TnW5N1emWwZ4To[Y5{KHSqZTDwc5dmeiCxZjDhcpRq[2GwY3XyJIRzfWe| MUmyOVAyQTdyMR?=
HT-29  M4nCNWFxd3C2b4Ppd{BCe3OjeR?= MmjINY1O MkLKOFhp NX;jZ3VZTE2VTx?= MY\lcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> Mo\wNlQ5PDJzNUi=
Microglia  NFi4fmtCeG:ydH;zbZMhSXO|YYm= NX7XTlRJPW2P MViyOIg> M3j0WYRm[3KnYYPld{BpgXCxeHnhMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NXnYZm16OjR6MUi2NFE>
A2780cp M1;QUWFxd3C2b4Ppd{BCe3OjeR?= MlzJNk42dU1? NFHFNYkycA>? MXLk[GgzVw>? M336OIVvcGGwY3XzJINqe3CuYYTpck1qdmS3Y3XkJINmdGxiZHXheIg> NV3oeos1OjR6MUe5OFY>
HepG2 M4\LSmZ2dmO2aX;uJGF{e2G7 M1LPe|VuVQ>? MUO0bC=> NUntfWxRcW6lcnXhd4V{KEiOIILlcIVie2V? NYDBWotQOjR5MUO1PFc>
A549 NF3X[pBCeG:ydH;zbZMhSXO|YYm= NEHue4Q2dU1? M1nx[FQ5cA>? MoTN[IVkemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGxiZHXheIgh[W6mIHX4dJJme3Orb36gcIV3\Wy|IH;mJINie3Cjc3WtN{whSmWlbHnuMVEh[W6mIFzDN{1KUQ>? NWLRZ3NmOjR5ME[zNFM>
U2OS NUL4PGhESXCxcITvd4l{KEG|c3H5 M2K5TFExdU1? NF;qT2YzPGh? MojsbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 M2r4WFI1PjN7MEGz
Saos-2 NF7wWnZCeG:ydH;zbZMhSXO|YYm= MWixNI1O MoH5NlRp NGfE[JVqdnSnboPp[olmeyC2aHWg[5Jwf3SqIHnubIljcXSrb36gc4YhfGinIGWyU3Mh[2WubIOgbY5lfWOnZDDifUBFd3h? MUCyOFY{QTBzMx?=
A549 NVTYUVRWSXCxcITvd4l{KEG|c3H5 NHfwSFMyOG2P NXXoVlRDPDiq NY\YcW1m[WOlZXzldoF1\XNidHjlJJJm\HWldHnvckBw\iClZXzsJJZq[WKrbHn0fUBqdmS3Y3XkJIJ6KFCWWB?= MW[yOFYzPjd{Mh?=
HCT116  NE\FcGxCeG:ydH;zbZMhSXO|YYm= MlnvOY1O M3;rSlI1cA>? MoPJ[Y5p[W6lZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHHwbYdmdmmw NEDSb5MzPDZ{NkWyNi=>
HGC-27 MYDGeY5kfGmxbjDBd5NigQ>? MUixNI1O M3n3[FFp M1HhfolvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBtd3O|IHL5JHJCTDByMTDvdkBOUy1{MkC2 MY[yOFQyPjN2OR?=
U2OS  M4Pub2Z2dmO2aX;uJGF{e2G7 M3zUU|AvPS9zbV2= M2rPNVQ5cA>? NFrXVoZqdmS3Y3XzJJNidGmwb335Z4lvNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgcI9{ew>? MkTsNlQ{PTh|NEK=
MG-63 NID3XnhHfW6ldHnvckBCe3OjeR?= M3qyR|AvPS9zbV2= MVW0PIg> MlHnbY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> NXPDb5l7OjR|NUizOFI>
MG-63 M1Kwc2Fxd3C2b4Ppd{BCe3OjeR?= NHzv[JExNjVxMX3N NHTsW|E{Omh? NUfhUZRQ\W6qYX7j[ZMhe2GuaX7vcZlkcW5vaX7keYNm\CClZXzsJIFxd3C2b4Ppdy=> NYDV[YxkOjR|NUizOFI>
MG-63 MVXBdI9xfG:|aYOgRZN{[Xl? M4nPU|ExdU1? M4n5[VEzcA>? NH;KXXBmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? NX7mOoVwOjR|NUizNFE>
NTUB1 MkfxRZBweHSxc3nzJGF{e2G7 MWC1cW0> NXHsfJRrOS53aB?= MYXwc5RmdnSrYYTld{Bk\WynY3;4bYIucW6mdXPl[EBieG:ydH;zbZM> MmjINlQ{PDlzN{[=
T24 MYnBdI9xfG:|aYOgRZN{[Xl? NYrWN4x2PW2P NXP2XIpoOS53aB?= M4LUWJBwfGWwdHnheIV{KGOnbHXjc5hq[i2rbnT1Z4VlKGGyb4D0c5Nqew>? MV2yOFM1QTF5Nh?=
SGC-7901  NULYNFBVSXCxcITvd4l{KEG|c3H5 M3jCPFJuVQ>? NF\tVmYycA>? NYnKS5dwcW6lcnXhd4V{KEODLUSgbY5lfWOnZDDhdI9xfG:|aYO= M4\GUVI1OzJzM{Sw
SMMC-7721 MnrHRZBweHSxc3nzJGF{e2G7 NYLGT4JZOm2P NUezNpB{OWh? NI\HPYhqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= M1LnfVI1OzJzM{Sw
ECSCs  M{TNUmFxd3C2b4Ppd{BCe3OjeR?= MXWxNI1O NF:2O|M1cA>? MVzk[YNz\WG|ZYOgdoFx[W27Y3nuMZRz\WG2ZXSgZZBweHSxc3nz NH3XbpUzPDNzOUGwPS=>
MCF-7  MXPGeY5kfGmxbjDBd5NigQ>? NUXDTI1HOTCvTR?= NXLMZ3cyOjSq M{ftTYlvcGmkaYTzJJRp\SCjdYTvdIhi\3liaX7keYNm\CCkeTDjbIVud3SqZYLhdJkh\HK3Z4O= MVSyOFMyPTV5OB?=
UOK257 NIj0cXpCeG:ydH;zbZMhSXO|YYm= NUCw[YpsPW2P MmC1N4g> M4L3XIVvcGGwY3XzJJBi[2yrdHH4[YwudWWmaXH0[YQh[XCxcITvd4l{yqB? MkH3NlQ{ODV4MES=
ACHN-5968 NYTHWpRFSXCxcITvd4l{KEG|c3H5 MofyOY1O M3PwUVNp NHG3PHpmdmijbnPld{Bx[WOuaYThfIVtNW2nZHnheIVlKGGyb4D0c5Nqe8Li Mmq3NlQ{ODV4MES=
Huh7 MXTBdI9xfG:|aYOgRZN{[Xl? MXmycW0> NV7hVnNXOTKq NXLTe3A6TE2VTx?= MmLqbY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= M{TxOlI1Ojl5M{Cw
Hep3B MnTORZBweHSxc3nzJGF{e2G7 Mn7RNo1O NGnDXZcyOmh? MX7EUXNQ Ml75bY5pcWKrdIOgRXpFQDB3NT3pcoR2[2WmIHPlcIwh\GWjdHi= NXmy[IFEOjR{OUezNFA>
RKO MlHwSpVv[3Srb36gRZN{[Xl? MmT3No1O MVixbC=> NWXmN|FpTE2VTx?= NHnucW1mdmijbnPld{Bk\WyuIHTlZZRpKGK7IHflcIRidmGveXPpci=> M2nERVI1OjlzN{e3
HepG2 E47 NY\ac3BjTnWwY4Tpc44hSXO|YYm= MYqyMlVuVQ>? MmDvOFhp MnnXbY5kemWjc3XzJJRp\SC2b4jpZ4l1gSCxZjDBRUwhSlORLDDhcoQhS0OuNB?= NYP0V2RTOjR{N{O3N|g>
LoVo  NXPo[WoxSXCxcITvd4l{KEG|c3H5 M2Ky[lVuVQ>? MUS0PIg> NW\JN2Uy\W6qYX7j[ZMhTEODLXnu[JVk\WRiYYDvdJRwe2m|Lh?= NET2eXUzPDJyMUixNi=>
WiDr NXLxXo57TnWwY4Tpc44hSXO|YYm= NVXh[mFrOTCvTR?= M1vSfVFp MknxbY5pcWKrdIOgVGNDVC2rbnT1Z4VlKEyFMzDJTUBmgHC{ZYPzbY9v MlLqNlQyQTB2OEm=
H1299  NFm0OYJHfW6ldHnvckBCe3OjeR?= NGnwV2QyOG2P M1PrclRp NYTzemJzcW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? Mn:0NlQyPzN{MEi=
H460 MYrGeY5kfGmxbjDBd5NigQ>? MVixNI1O M4\YV|Rp MVXpcoNz\WG|ZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> M4rDO|I1OTd|MkC4
A549 MX;GeY5kfGmxbjDBd5NigQ>? NYD4VJM4OTCvTR?= Mnj2OIg> MUHpcohq[mm2czDheZRweGijZ4mgbY5lfWOnZDDifUBqenKjZHnheIlwdg>? M4rwTlI1OTR{N{O1
Hep3B MlfMRZBweHSxc3nzJGF{e2G7 MlnSOY1O MmDoNlRp NGXWT2RifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> MXeyOFA3PjZ7Mx?=
SMMC-7721 MkH2RZBweHSxc3nzJGF{e2G7 MnPZOY1O NEDBcokzPGh? NHToOmhifHSnboXheIV{KFSQRj5OtUBxem:2ZXP0bY9vKGGpYXnud5Qhe2W{dX2gd5Rien[jdHnvck1u\WSrYYTl[EBieG:ydH;zbZM> MmXYNlQxPjZ4OUO=
HO8910 NYWwfIZzSXCxcITvd4l{KEG|c3H5 M2q0TFExdU1? MlzHNVJp NFy5OG1mdmijbnPld{BDOTlvaX7keYNm\CCjcH;weI9{cQ>? M3fuOVI{QTh|NkGw
MCF7 NH3NdnVHfW6ldHnvckBCe3OjeR?= MYe1cW0> NWLofmJlOjSq M3[ycIlv[3KnYYPld{BEfU9iaX7keYNm\CClZXzsJIRm[XSq M1PKW|I{QTZ{NkK5
HONE-1  NXfrTo9uTnWwY4Tpc44hSXO|YYm= NHfSVlA2dU1? M1PTPFFp NF;EWVZz\XC{ZYPz[ZMhPnJvbXXkbYF1\WRiUl;TJJBzd2S3Y4Tpc44> M1XXZ|I{QDl{M{W4
HeLa MUnGeY5kfGmxbjDBd5NigQ>? Mn3uNVBuVQ>? Mn2yNog> NXroV2lPe3WycILld5NmeyCOQ{OgTWkh\XiycnXzd4l{d25? Mkm3NlM5PjR5M{i=
HepG2 MnfVSpVv[3Srb36gRZN{[Xl? MVexNI1O M1fmeFI1cA>? MVzpcohq[mm2czDzbXRKT0GULTDhcoQhUEKVUz3pcoR2[2WmIHH1eI9xcGGpeR?= MVyyN|gyPzB2MB?=
SH-SY5Y MYnGeY5kfGmxbjDBd5NigQ>? NVvaTJhNOW2P MmPvNlRp NYTYTGlOcW6qaXLpeJMhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRQS1B? M{H5S|I{PzR|MUS4
SH-SY5Y NXzKN5JUSXCxcITvd4l{KEG|c3H5 MmnLOY1O NF3Pc5QycA>? NEnSbHFi[m:uaYPo[ZMh[2WuYYP0do9tKG6ndYLvdJJwfGWldHn2[UBm\m[nY4S= Ml;SNlM3OTl|OUW=
PC12  NU\4fnZiTnWwY4Tpc44hSXO|YYm= MXKxNI1O MoDtNlRp Mn;1e4F1\XJ? MWhCpIlvcGmkaYTzJINpgW2xdIL5dJNqdi2uaXvlJJBzd3SnYYPvcYFtKGGldHn2bZR6Ng>? MUeyN|YxOzl5OR?=
OV2008 M{HVWGFxd3C2b4Ppd{BCe3OjeR?= NFfCdlI2dU1? NHyz[4kzPGh? MljiZ49vfmW{dIOgSnR[PzJyIIfpeIghS0SGUDDpcpRwKGGwIHHk[Il1cX[nIHXm[oVkfCC2b4fhdoR{KGurbHzpcochd3[jcnnhckBk[W6lZYKgZ4VtdHN? Ml7rNlM2QTJ{OEG=
A2780 M{H3bWFxd3C2b4Ppd{BCe3OjeR?= NWjsfYt2PW2P M3XWeVI1cA>? M2LPWINwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| NHK1RYgzOzV7MkK4NS=>
Saos-2  MoTNRZBweHSxc3nzJGF{e2G7 Mk\0NY1O MkXUPVZp MnfBbY5kemWjc3XzJINmdGxiZHXheIghcW6mdXPl[EBjgSCSQ2i= NIn6WWUzOzV4M{G3NS=>
1321N1 MmXjR5l1d3SxeHnjbZR6KEG|c3H5 MVi1cW0> M1iyZVI1cA>? M4\F[JBzd3SnY4TzJINmdGxiYXfhbY5{fCCSQ16tbY5lfWOnZDD0c5hq[2m2eR?= NX;pUYRpOjN3MkWyOlU>
SH-SY5Y Mk\GR5l1d3SxeHnjbZR6KEG|c3H5 MnvQOY1O MlWzNlRp NULmSlk1cW6lcnXhd4V{KFCFTjD0c5hq[2m2eR?= NVPYOGVoOjN3MkWyOlU>
HT-29  Ml3pSpVv[3Srb36gRZN{[Xl? NF;pfmcydU1? NILQbGY1QC97Nni= MVXpcohq[mm2czDBUXBMKGmwZIXj[ZMh[XW2b4DoZYdq[yClZXzsJIRm[XSq MVGyN|UxQDJ5Mh?=
OR6 MnrmSpVv[3Srb36gRZN{[Xl? NHfaU2syOG2P NY\XOJJOPzKq MUXzeZBxemW|c3XzJGhEXiC{ZYDsbYNifGmxbjDhcoQh\m:{bXH0bY9vKG:oIHH1eI9xcGGpb4PvcYV{ MljmNlM{QTV6N{W=
Hela  M3jjXWZ2dmO2aX;uJGF{e2G7 NETDR|U2dU1? M3HKZ|I1cA>? NYfKSWVLcW6qaXLpeJMhe3Sjco\heIlwdi2rbnT1Z4VlKGG3dH;wbIFogQ>? M4rvNlI{Ozl3Nke5
MCF-7  M33TfGZ2dmO2aX;uJGF{e2G7 NIXYcJI2dU1? MXiyOIg> MlrvbY5pcWKrdIOgd5Rien[jdHnvck1qdmS3Y3XkJIF2fG:yaHHnfS=> MVWyN|M6PTZ5OR?=
HUVECs NVLEVWcxTnWwY4Tpc44hSXO|YYm= M4K2cFNuVQ>? Mn;5NlRp Mnz2Zoxw[2u|IITo[UBxem:2ZXP0bZZmKGWoZnXjeEBw\iC{ZYP2[ZJifHKxbDDifUBqdmirYnn0bY5oKGG3dH;wbIFogQ>? NFzRRWkzOzN3OEmyPC=>
T24 NUH5eGY3TnWwY4Tpc44hSXO|YYm= MlLPNVBuVQ>? MYmxbC=> NHnRZpNz\WS3Y3XzJJRp\SClbHXheoFo\SCxZjDMR|Mh[W[2ZYKgZoFq[2GuaX6geJJm[XSvZX70 MViyN|M2PDB6MB?=
U251MG  MYfGeY5kfGmxbjDBd5NigQ>? MmP1N41O MlrSNYg> NHzuemd{fXCycnXzd4V{KEyFMz3JTUBxem:2ZXnuJIV5eHKnc4Ppc44> MnnmNlM{Ozh4MUi=
GTL-16  MkHxRZBweHSxc3nzJGF{e2G7 MoSyOY1O NGjMeIUzPGh? NF3EV3dz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHzJINwdXCjcnXkJJRwKGOnbHzzJJRz\WG2ZXSge4l1cCCPRWSgbY5pcWKrdH;ydy=> MVeyN|MyOzR7MB?=
T-47D NGXudJdHfW6ldHnvckBCe3OjeR?= MmjUNVBuVQ>? NWnVcFlROmh? NFj0SYtqdmirYnn0d{BifXSxcHjh[5kheHKxY3Xzd{BidmRiaX7jdoVie2W|IILhdIFugWOrbjDpcoR2[2WmIHHwc5B1d3Orcx?= NXrZb|lQOjN|MECwNlY>
PaCa44 MnvLRZBweHSxc3nzJGF{e2G7 MlXWNk42dU1? MVmxbC=> NVXxPHRVemWmdXPld:Kh\2WwaYDpck1u\WSrYYTl[EBieG:ydH;zbZM> Mm\INlMyOjRzMUK=
MDA-MB231 MnrQSpVv[3Srb36gRZN{[Xl? MUO1cW0> NVPBSXljOWh? MVXpcoNz\WG|ZYOgdoV{fmW{YYTyc4wudWWmaXH0[YQh[2G|cHHz[UBi[3SrdnH0bY9vKGGwZDDj[YxtKGSnYYTo M12xOlI{ODh6OEWw
HeLa NYKzcoNJSXCxcITvd4l{KEG|c3H5 NFXIb3cyOG2P MnnpNog> NUPCcIxX\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0cYVvfCC5aYToJHBGUQ>? NXP3SFQ1OjNyMECxN|U>
SK-HEP-1 MoD5RZBweHSxc3nzJGF{e2G7 MkLTNVBuVQ>? NXThU4FNOWh? NHHTNnBxem:2ZXP0d{Bi\2GrboP0JIF2fG:yaHHnfUBidmRiaX7keYNmeyCjcH;weI9{cXNiaX6gZpVn[Wyrbj30doVifGWmIHPlcIx{ M1XPdlIzQDV6NkS5
HepG2 M17sUWFxd3C2b4Ppd{BCe3OjeR?= NXvGZ2JUO22P NX\UVlJjPWh? M1nyRZJm\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDRSJM> MXGyNlg{PjV7NR?=
MCF-7  M1TxXmZ2dmO2aX;uJGF{e2G7 M4P2fFJuVQ>? NGnzVWUzPGh? M4jWUIlvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= MXeyOFk4ODZ5Nh?=
MDA-MB-231 M33VN2Z2dmO2aX;uJGF{e2G7 MlvqNo1O MWiyOIg> NFPOZ|BqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCWTdMg NETuVXIzPDl5ME[3Oi=>
MCF-7  NWLvZo96TnWwY4Tpc44hSXO|YYm= NUn6V5RzOm2P Mke4OFhp NUPaXJIzeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq NHnF[JIzPDl5ME[3Oi=>
MDA-MB-231 NG\LZZhHfW6ldHnvckBCe3OjeR?= NF3EOY0zdU1? NWDEUJVsPDiq NXr0UGxjeHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq M{O3WFI1QTdyNke2
PANC-1  M4rQ[mFxd3C2b4Ppd{BCe3OjeR?= NHTBO4wydU1? MoTzOFhp NEXZNFJFVVOR Mo\6[Y5p[W6lZYOgZo9zfGW8b33pZk1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> M17JU|I1QDR{MUW4
MDA-MB 231 MmLyRZBweHSxc3nzJGF{e2G7 MmTKOY1O NFnmfZQxNjWq MofacY9lfWyjdHXzJHRw[2:vaX9CsuKhcW6mdXPl[EBieG:ydH;zbZM> MmXHNlQ5OzB5OEG=
Microglia  NY\qOYRESXCxcITvd4l{KEG|c3H5 NGHsdWo2dU1? NH7GV|kzPGh? NXLBNG5O\GWlcnXhd4V{KGi7cH;4bYEucW6mdXPl[EBk\WyuIHTlZZRp M{fHflI1QDF6NkCx
A2780cp M4TNWGFxd3C2b4Ppd{BCe3OjeR?= M3zRdlIvPW2P NYnXR|BXOWh? MVjk[GgzVw>? MknC[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MnviNlQ5OTd7NE[=
HepG2 MWPGeY5kfGmxbjDBd5NigQ>? MkTNOY1O MVi0bC=> M{DBdIlv[3KnYYPld{Bk\WyudXzhdkBt\X[nbIOgc4YhUE{EoB?= MWGyOFcyOzV6Nx?=
U2OS MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVSxNI1O NITFRpAzPGh? M1rmSIlvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JGRwgA>? MVWyOFY{QTBzMx?=
HCT116 NUL1d|l4SXCxcITvd4l{KEG|c3H5 NED0e4g2dU1? Mm\GNlRp M4HTN2ROW09? M3PFXoVvcGGwY3XzJIFxcWenbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MVSyOFYzPjV{Mh?=
MCF-7  M4XON2Fxd3C2b4Ppd{BCe3OjeR?= NX\ZdJZbOC5zbV2= M1frSlZp MWLlcohidmOnczDzbZJ1cW6xbD3pcoR2[2WmIHHwc5B1d3Orcx?= MljjNlI4PTF7OEm=
PC-3  MV\BdI9xfG:|aYOgRZN{[Xl? MnGyNo1O NFjoN3QzcA>? MVfpcoNz\WG|ZYOgU3JKNWmwZIXj[YQh[2WubDDk[YF1cA>? MmnLNlI4PDV3OEC=
U251  M2nFcGFxd3C2b4Ppd{BCe3OjeR?= MoPMOY1O NUf4NGpxOjSq NVLUPFdOcW6lcnXhd4V{KFNzLXnu[JVk\WRiY3XscEBl\WG2aB?= MkLFNlI2Pzl5OEi=
HeLa  MmfSRZBweHSxc3nzJGF{e2G7 MnnGOY1O M2PsdVI1cA>? M4Hre4lv\HWlZYOgZ4F{eGG|ZT3k[ZBmdmSnboSgZ4VtdCCmZXH0bC=> NGi1eG0zOjV2NUGyPC=>
A549 NFXkc5JHfW6ldHnvckBCe3OjeR?= NHnBbosxNjGvTR?= MlTkNlRp MlvPd5VxeHKnc4Pld{BUXTFzMke0MYlv\HWlZXSgZ4VtdCCmZXH0bC=> NV\QNWtZOjJ2Nk[5OlA>
pDCs NGT6WW1HfW6ldHnvckBCe3OjeR?= MYOxNI1O M4\X[VAvPWh? NY\0T2Z1yqC{ZXT1Z4V{KHSqZTDpcoR2[3Srb36gc4YhUU[QLd8xJIJ6KHO|Ul7BOFA> NXLzR3BKOjJ|OU[1PVk>
BGC-823 M{WxSWZ2dmO2aX;uJGF{e2G7 MnG4OY1O MojpNog> MlLobY5pcWKrdIOgeIhmKHKjdHWgc4Yh[XW2b4DoZYdq[yClZXzsdy=> NWfwd3dyOjJ|MkKxOVI>
U937 MU\GeY5kfGmxbjDBd5NigQ>? MnXUNo1O NIKzRnMyOmh? MYfk[YNz\WG|ZYOgeIhmKGG3dH;wbIFogSC{YYTpc:Kh MlXNNlIyPTVzNUC=
Marc-145 NE\hTHJHfW6ldHnvckBCe3OjeR?= M3\6O|VuVQ>? MkfJNVIwOjRxM{\o NUXRT|FyemWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u NUTtXlZLOjJzMUm5NFA>
HBx  NUnDfVJDSXCxcITvd4l{KEG|c3H5 NVLi[ZNGOTCvTR?= NUHidmFnPDiq NH7MbXpFVVOR MVzpcoNz\WG|ZYOgZ4VtdCCmZXH0bC=> NUf4fGhXOjJyMkCwO|g>
MCF-7 NYq2fIxmTnWwY4Tpc44hSXO|YYm= MYKxNI1O MVq0PIg> M1ewW4Jtd2OtczDheZRweGijZ4mgbY5lfWOnZDDifUBjd3K2ZYrvcYlj MU[yNVk{OTl|Nx?=
RMPI8226  NHjPbIdHfW6ldHnvckBCe3OjeR?= M{Hk[FVuVQ>? NIfvblEycA>? NH2yVVB{fXCycnXzd4V{KHSqZTDs[ZZmdCCxZjDheZRweGijZ4mgeY5l\XJiboX0dolmdnRiZHXwcIV1cW:w NWrWR3luOjF7MUW2NlA>
PC12/TetOn MljHSpVv[3Srb36gRZN{[Xl? MWewMlEwOW2P NIG1cW4yQGh? MnzzcIVi\HNidH:g{tEue3mwKGfULUBi[2O3bYXsZZRqd25uIITvfIlkcXS7LDDhcoQhd2yrZ3;t[ZIh\m:{bXH0bY9vyqB? NX\kcmQ5OjF7ME[2OVk>
HeLa  Ml:3R5l1d3SxeHnjbZR6KEG|c3H5 NYHhcnV1Om2P MnqwNlRp NU\HdVJZcW6qaXLpeIV{KHSqZTDjfZRwfG:6aXPpeJkhd2Zic3nsbYJqdmmwIITvJGhmVGFiY3XscJMv Mny3NlE5PzV|OEW=
Jurkat NEfHSJBHfW6ldHnvckBCe3OjeR?= NXvXepc4OTCvTR?= NHz2NI4ycA>? NXjre3VT\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFMz3JTUBidmRidHjlJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MkXzNlE5PjRyM{e=
K562 M1jlOmZ2dmO2aX;uJGF{e2G7 MUexNI1O MU[xbC=> NXvNOVgy\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFMz3JTUBidmRidHjlJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> NYHvbW1JOjF6NkSwN|c>
Nara-H MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXyT5R{PW2P MmjPOFhp NXrwWldZ\W6qYX7j[ZMhfGWvc3nyc4xqdXW|bXXkbYF1\WRic4XwdJJme3Orb36gc4YhVmG{YT3IJINmdGxicILvcIln\XKjdHnvci=> MV2yNVgxPTB|Mx?=
HUVECs MUjGeY5kfGmxbjDBd5NigQ>? NHmyOpEyOG2P MnjWNE42cA>? NIfnPWNl\WO{ZXHz[ZMhfGinIFHHSU1DW0GrbnT1Z4VlKGG3dH;wbIFogSCuZY\l NUXEVGZqOjF2Nki1PVI>
HepG2 NHzBRmNCeG:ydH;zbZMhSXO|YYm= NGnqSmIzdU1? NV;a[HhrOWh? M1jXeIVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJINmdGxiZHXheIg> NH;TfogzOTR3M{[5NS=>

... Click to View More Cell Line Experimental Data

In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL (67.04 mM) warming
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)
In vivo water 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID